Led · Equity · Jul 2024

Phylos is a Portland-based cannabis genetics company that applies modern plant-breeding techniques, large-scale field data, and rapid iteration to create uniform, high-yielding, and disease-resistant F1 hybrid cannabis cultivars. Its core product is a genetics platform that delivers reliable seed lines and a continuously expanding portfolio of genetically and phenotypically distinct hybrids aimed at improving consistency, scale, and quality for cultivators. The company emphasizes data-driven breeding to boost yield, predictability, and production efficiency across markets. Through long-standing collaboration with major producer Organigram, Phylos provides priority access to select genetics while continuing to broaden its offerings to the wider industry. The newly announced funding will accelerate development of new traits and seed lines and advance the company’s broader breeding roadmap. Although no revenue or user figures were disclosed, the press release positions Phylos as a key enabler of the next phase of large-scale, seed-based cannabis production driven by predictable genetics.

Led · Equity · Jun 2024

Sanity Group, founded in Berlin in 2018, develops medicinal cannabis, wellbeing and cosmetic cannabinoid products and operates brands/subsidiaries such as AVAAY Medical, Vayamed, Endosane Pharmaceuticals and VAAY. The company maintains a large German distribution network of over 2,000 pharmacies and works with approximately 5,000 physicians, holding roughly a 10% share of the German medical cannabis market; its AVAAY medical brand is estimated to be number two. Sanity is participating in a Swiss recreational cannabis pilot in Basel with one store operational and plans to expand its retail footprint in Switzerland. The company intends to invest in proprietary distribution channels to capture new medical consumers and is planning initiatives expected to provide access to over 100,000 patients and support recreational pilot expansion. Sanity’s product mix spans pharmaceuticals, medical cannabis, and wellbeing/cosmetic offerings, and it operates a storage facility near Frankfurt for extracts and flower. Sanity Group develops medicinal cannabis, finished pharmaceuticals, medical products, digital applications, wellbeing products and natural cosmetics that utilize cannabinoids and the endocannabinoid system. The group comprises Vayamed and AVAAY Medical (medicinal cannabis), Endosane Pharmaceuticals (finished pharmaceuticals), Belfry Medical (medical products and digital applications), VAAY (wellbeing) and This Place (natural cosmetics). It operates a production and processing facility for cannabis extracts near Frankfurt am Main and employs around 120 people across medical, consumer health and science functions. Founded in Berlin in 2018, the company aims to improve quality of life through cannabinoid-based products and therapies. Sanity Group plans to use new funding to accelerate growth, enable European expansion and strengthen research and development. The company has raised over $100 million in total funding to date. Sanity Group is a Berlin-based cannabis and digital health startup that builds a cannabis-based platform for mental health and chronic pain management. Its offering includes a medical device and digital therapy diary that tracks administered active ingredients (THC, CBD and other cannabinoids) to quantify dosing. The company closed a $44.2M Series A, bringing total funding to $73M; the round is reported as the largest cannabis funding round in Europe to date. Proceeds will be used to expand the Group’s medical division in Europe and to build an EU‑GMP‑compliant research and production facility near Frankfurt. Management says it is expanding geographically into the Czech Republic and Poland, targeting the U.K., and expects France to open next year. Prior investors include HV Capital, TQ Ventures, Atlantic Food Labs, Cherry Ventures, Bitburger Ventures and SevenVentures, and celebrity angels include will.i.am, Scooter Braun and Alyssa Milano. Sanity Group is a Berlin-based medical cannabis and wellness company operating two business units: Sanatio Pharma, focused on developing new medical cannabis therapies and pharmaceuticals, and VAAY, a consumer wellness brand. The company is fully licensed and currently operational. Founded in 2018 by Finn Hänsel and Fabian Friede, Sanity Group combines medical and consumer wellness offerings. It completed a €20m funding round to support strategic initiatives. The funds will be used to drive projects that expand access to medical and medically-related cannabis products and advance its product programs.

Led · Series B · Mar 2023

Founded in 2016, Greentank designs and manufactures vaporization hardware and heating technology for cannabis and nicotine vaping devices. Its flagship product, the Quantum Chip, is a proprietary heating technology intended to replace ceramic coils and was largely developed with funds from its 2023 Series B. The company has partnered with AIR Global (including on a 2023 device called Vant) and recently hired Chris Gemmell as chief product and innovation officer. Greentank is preparing a Pre-Market Tobacco Application (PMTA) for the U.S. FDA, and the recent strategic investment includes supply assurances important to that process. To date the company has raised about $56 million USD in total capital.

Led · Equity · Oct 2020

Hyasynth Biologicals is a Montreal, Canada–based biotechnology company founded in 2014 that produces cannabinoids through fermentation using patent-pending yeast strains and enzymes. Its Better Cannabinoids technology enables scalable, low-cost production of major cannabinoids (THC, CBD, CBG) and rare/minor cannabinoids not typically accessible by plant cultivation. The company announced the first commercial sale of CBDa produced and extracted from yeast, a milestone tied to investor tranches. Hyasynth positions biosynthesis as pesticide-free, consistent, and lower-cost versus plant cultivation, with a smaller environmental footprint and suitability for food and pharmaceutical infrastructure. Investors named in the articles include SOSV/IndieBio, AngesQuebec and strategic investor Organigram Holdings Inc. Organigram also holds commercial purchase rights to Hyasynth’s production on discounted terms for a defined period.